Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment
Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern treatment strategies, although approximately 20% will die after relapse or progressive disease. The histologic hallmark of the disease is...
Uloženo v:
| Vydáno v: | Journal of clinical oncology Ročník 29; číslo 14; s. 1812 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
10.05.2011
|
| Témata: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern treatment strategies, although approximately 20% will die after relapse or progressive disease. The histologic hallmark of the disease is the presence of the characteristic Hodgkin Reed-Sternberg (HRS) cells in classical HL and so-called lymphocyte-predominant (LP) cells in nodular lymphocyte-predominant HL. HL is unique among all cancers because malignant cells are greatly outnumbered by reactive cells in the tumor microenvironment and make up only approximately 1% of the tumor. Expression of a variety of cytokines and chemokines by the HRS and LP cells is believed to be the driving force for an abnormal immune response, perpetuated by additional factors secreted by reactive cells in the microenvironment that help maintain the inflammatory milieu. The malignant HRS and LP cells manipulate the microenvironment, permitting them to develop their malignant phenotype fully and evade host immune attack. Gene expression signatures derived from non-neoplastic cells correlate well with response to initial and subsequent therapies, reflecting their functional relevance. Recent biomarker studies have added texture to clinical outcome predictors, and their incorporation into prognostic models may improve our understanding of the biologic correlates of treatment failure. Moreover, recent preclinical and clinical studies have demonstrated that the tumor microenvironment represents a promising therapeutic target, raising hope that novel treatment strategies focused on the interface between malignant and reactive cells will soon emerge. |
|---|---|
| AbstractList | Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern treatment strategies, although approximately 20% will die after relapse or progressive disease. The histologic hallmark of the disease is the presence of the characteristic Hodgkin Reed-Sternberg (HRS) cells in classical HL and so-called lymphocyte-predominant (LP) cells in nodular lymphocyte-predominant HL. HL is unique among all cancers because malignant cells are greatly outnumbered by reactive cells in the tumor microenvironment and make up only approximately 1% of the tumor. Expression of a variety of cytokines and chemokines by the HRS and LP cells is believed to be the driving force for an abnormal immune response, perpetuated by additional factors secreted by reactive cells in the microenvironment that help maintain the inflammatory milieu. The malignant HRS and LP cells manipulate the microenvironment, permitting them to develop their malignant phenotype fully and evade host immune attack. Gene expression signatures derived from non-neoplastic cells correlate well with response to initial and subsequent therapies, reflecting their functional relevance. Recent biomarker studies have added texture to clinical outcome predictors, and their incorporation into prognostic models may improve our understanding of the biologic correlates of treatment failure. Moreover, recent preclinical and clinical studies have demonstrated that the tumor microenvironment represents a promising therapeutic target, raising hope that novel treatment strategies focused on the interface between malignant and reactive cells will soon emerge. Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern treatment strategies, although approximately 20% will die after relapse or progressive disease. The histologic hallmark of the disease is the presence of the characteristic Hodgkin Reed-Sternberg (HRS) cells in classical HL and so-called lymphocyte-predominant (LP) cells in nodular lymphocyte-predominant HL. HL is unique among all cancers because malignant cells are greatly outnumbered by reactive cells in the tumor microenvironment and make up only approximately 1% of the tumor. Expression of a variety of cytokines and chemokines by the HRS and LP cells is believed to be the driving force for an abnormal immune response, perpetuated by additional factors secreted by reactive cells in the microenvironment that help maintain the inflammatory milieu. The malignant HRS and LP cells manipulate the microenvironment, permitting them to develop their malignant phenotype fully and evade host immune attack. Gene expression signatures derived from non-neoplastic cells correlate well with response to initial and subsequent therapies, reflecting their functional relevance. Recent biomarker studies have added texture to clinical outcome predictors, and their incorporation into prognostic models may improve our understanding of the biologic correlates of treatment failure. Moreover, recent preclinical and clinical studies have demonstrated that the tumor microenvironment represents a promising therapeutic target, raising hope that novel treatment strategies focused on the interface between malignant and reactive cells will soon emerge.Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern treatment strategies, although approximately 20% will die after relapse or progressive disease. The histologic hallmark of the disease is the presence of the characteristic Hodgkin Reed-Sternberg (HRS) cells in classical HL and so-called lymphocyte-predominant (LP) cells in nodular lymphocyte-predominant HL. HL is unique among all cancers because malignant cells are greatly outnumbered by reactive cells in the tumor microenvironment and make up only approximately 1% of the tumor. Expression of a variety of cytokines and chemokines by the HRS and LP cells is believed to be the driving force for an abnormal immune response, perpetuated by additional factors secreted by reactive cells in the microenvironment that help maintain the inflammatory milieu. The malignant HRS and LP cells manipulate the microenvironment, permitting them to develop their malignant phenotype fully and evade host immune attack. Gene expression signatures derived from non-neoplastic cells correlate well with response to initial and subsequent therapies, reflecting their functional relevance. Recent biomarker studies have added texture to clinical outcome predictors, and their incorporation into prognostic models may improve our understanding of the biologic correlates of treatment failure. Moreover, recent preclinical and clinical studies have demonstrated that the tumor microenvironment represents a promising therapeutic target, raising hope that novel treatment strategies focused on the interface between malignant and reactive cells will soon emerge. |
| Author | Connors, Joseph M Steidl, Christian Gascoyne, Randy D |
| Author_xml | – sequence: 1 givenname: Christian surname: Steidl fullname: Steidl, Christian organization: Department of Pathology and Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Room 5-113, Vancouver, BC V5Z 1L3, Canada – sequence: 2 givenname: Joseph M surname: Connors fullname: Connors, Joseph M – sequence: 3 givenname: Randy D surname: Gascoyne fullname: Gascoyne, Randy D |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21483001$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1PwzAUxC1URD9gZ0LZOqXYjhPbbKgCCirqAnNknNfWNLaDnVTqf08qitTp7p5-d8Mbo4HzDhC6JXhGKMb3b_PVjOI-ZXQmGCYXaERyylPO83xw5odoHOM3xoSJLL9CQ3o0fRyh3buvQXe1Ckmj2q3fgINoYuLXycJXm51x05jUB9tsvVUPiXE6gIrGbRLYmwqchiPabiExtvGhVWcXa3Tw4PYmeGfBtdfocq3qCDcnnaDP56eP-SJdrl5e54_LVGeyaFPFMeEEFFSAMQMm1xlIkVUqq1ghNZcMKBBdCCa4FlLLrJdc9BSXFVsDnaDp324T_E8HsS2tiRrqWjnwXSxFkReS9ZWevDuR3ZeFqmyCsSocyv__0F_vUGsr |
| CitedBy_id | crossref_primary_10_1038_bcj_2014_58 crossref_primary_10_1016_j_celrep_2024_114605 crossref_primary_10_1016_j_ctrv_2013_09_005 crossref_primary_10_1016_j_compbiolchem_2013_04_003 crossref_primary_10_1371_journal_pone_0114345 crossref_primary_10_1016_j_leukres_2024_107457 crossref_primary_10_3390_cancers12040877 crossref_primary_10_1080_10428194_2017_1300898 crossref_primary_10_1182_bloodadvances_2021005304 crossref_primary_10_1186_s12885_020_07026_6 crossref_primary_10_3390_pathogens7010028 crossref_primary_10_3892_ijo_2014_2395 crossref_primary_10_1186_s13073_015_0218_3 crossref_primary_10_1097_PAS_0000000000000473 crossref_primary_10_3389_fimmu_2022_829943 crossref_primary_10_1002_path_5043 crossref_primary_10_1016_j_jfma_2013_09_001 crossref_primary_10_1007_s00259_013_2686_2 crossref_primary_10_3892_mmr_2018_8911 crossref_primary_10_3389_fonc_2025_1515250 crossref_primary_10_1016_j_it_2017_04_004 crossref_primary_10_1182_blood_2012_04_421057 crossref_primary_10_1111_bjh_15658 crossref_primary_10_3109_10428194_2014_963081 crossref_primary_10_1182_blood_2012_03_413146 crossref_primary_10_1007_s40259_013_0077_7 crossref_primary_10_1111_j_1600_065X_2012_01113_x crossref_primary_10_1080_10428194_2017_1289520 crossref_primary_10_3390_ijms26157508 crossref_primary_10_3390_cancers10060163 crossref_primary_10_1016_j_yexmp_2021_104606 crossref_primary_10_1038_s41598_019_49015_1 crossref_primary_10_3109_10428194_2014_917636 crossref_primary_10_1016_S2352_3026_14_00039_8 crossref_primary_10_1080_1744666X_2023_2294943 crossref_primary_10_14694_EdBook_AM_2012_32_83 crossref_primary_10_1517_14728214_2014_912277 crossref_primary_10_3109_10428194_2013_847938 crossref_primary_10_1016_j_acthis_2021_151750 crossref_primary_10_1111_ijlh_13559 crossref_primary_10_1182_blood_2022017147 crossref_primary_10_1182_blood_2016_11_746701 crossref_primary_10_1002_pbc_25193 crossref_primary_10_1002_jha2_41 crossref_primary_10_1097_QAD_0000000000000980 crossref_primary_10_1053_j_semnuclmed_2017_09_002 crossref_primary_10_1002_pbc_24423 crossref_primary_10_1158_1078_0432_CCR_19_2356 crossref_primary_10_1016_j_yexmp_2014_09_014 crossref_primary_10_1080_10428194_2019_1636983 crossref_primary_10_3109_10428194_2013_818144 crossref_primary_10_1002_path_4306 crossref_primary_10_1007_s00292_016_0199_z crossref_primary_10_3390_ijms20215503 crossref_primary_10_1038_s41409_018_0342_y crossref_primary_10_1186_1471_2407_13_250 crossref_primary_10_1002_jha2_432 crossref_primary_10_1038_s41375_020_0737_9 crossref_primary_10_1111_bjh_12120 crossref_primary_10_3390_cancers5020714 crossref_primary_10_3390_cancers13143634 crossref_primary_10_1080_17474086_2021_1935851 crossref_primary_10_1186_s12916_016_0711_6 crossref_primary_10_3390_diagnostics12030573 crossref_primary_10_1080_10428194_2016_1248966 crossref_primary_10_3389_fonc_2021_719140 crossref_primary_10_1200_JCO_2012_43_4589 crossref_primary_10_1002_jev2_12121 crossref_primary_10_1177_1460458216655188 crossref_primary_10_3390_cancers13040884 crossref_primary_10_3390_cancers10040091 crossref_primary_10_1002_path_4558 crossref_primary_10_2217_BMM_15_30 crossref_primary_10_1053_j_seminhematol_2024_05_001 crossref_primary_10_1002_hon_2827 crossref_primary_10_1371_journal_pone_0125203 crossref_primary_10_3892_etm_2024_12453 crossref_primary_10_1182_blood_2012_02_410647 crossref_primary_10_1038_s41572_020_0189_6 crossref_primary_10_1182_blood_2017_06_788877 crossref_primary_10_1097_MOH_0000000000000158 crossref_primary_10_1186_s13000_019_0912_3 crossref_primary_10_1200_JCO_2011_37_1377 crossref_primary_10_3390_cancers14205072 crossref_primary_10_1080_10428194_2021_2023744 crossref_primary_10_1371_journal_pone_0138747 crossref_primary_10_1007_s00259_014_2815_6 crossref_primary_10_1182_blood_2012_06_439570 crossref_primary_10_3390_jcm11216574 crossref_primary_10_1002_ajh_23566 crossref_primary_10_1002_gcc_22276 crossref_primary_10_1007_s13277_016_5118_7 crossref_primary_10_1111_cas_15122 crossref_primary_10_1016_j_humpath_2013_02_010 crossref_primary_10_1182_bloodadvances_2021005343 crossref_primary_10_1016_j_humimm_2022_08_013 crossref_primary_10_1182_blood_2016_02_700773 crossref_primary_10_1073_pnas_1312509110 crossref_primary_10_1016_S2352_3026_20_30221_0 crossref_primary_10_1111_j_1365_2141_2011_08975_x crossref_primary_10_1002_ajh_25054 crossref_primary_10_1111_bjh_13540 crossref_primary_10_1007_s00292_020_00774_z crossref_primary_10_1007_s12094_020_02297_8 crossref_primary_10_1002_1878_0261_12616 crossref_primary_10_1186_s43094_024_00590_9 crossref_primary_10_14694_EdBook_AM_2015_35_e479 crossref_primary_10_3109_10428194_2014_981174 crossref_primary_10_1080_10428194_2019_1709832 crossref_primary_10_1158_1078_0432_CCR_11_1942 crossref_primary_10_3390_cancers12030601 crossref_primary_10_3109_10428194_2015_1038709 crossref_primary_10_1007_s12308_019_00350_2 crossref_primary_10_1200_JCO_2011_39_9881 crossref_primary_10_1002_hon_2295 crossref_primary_10_1016_j_coi_2013_01_001 crossref_primary_10_1073_pnas_2105822118 crossref_primary_10_1200_JCO_2013_53_1194 crossref_primary_10_2217_imt_2017_0002 crossref_primary_10_3389_fonc_2021_654854 crossref_primary_10_1155_2019_9513701 crossref_primary_10_1182_blood_2018_08_870915 crossref_primary_10_1007_s00259_014_2973_6 crossref_primary_10_1038_s41598_025_16218_8 crossref_primary_10_1080_2162402X_2017_1389821 crossref_primary_10_1158_2159_8290_CD_16_0850 crossref_primary_10_1182_blood_2013_06_508044 crossref_primary_10_1593_tlo_12142 crossref_primary_10_3390_biomedicines10030579 crossref_primary_10_1158_1078_0432_CCR_18_1133 crossref_primary_10_1586_17474086_2015_1081562 crossref_primary_10_1080_10428194_2016_1185789 crossref_primary_10_1002_pbc_27307 crossref_primary_10_1016_j_bbcan_2011_11_002 crossref_primary_10_1016_j_clml_2014_10_001 crossref_primary_10_3390_ijms20102416 crossref_primary_10_1080_10428194_2018_1443336 crossref_primary_10_1182_blood_2018_07_864520 crossref_primary_10_1200_JCO_2011_35_9166 crossref_primary_10_1111_ejh_12770 crossref_primary_10_4161_cib_28602 crossref_primary_10_3389_fonc_2018_00147 crossref_primary_10_1177_2040620719846451 crossref_primary_10_1016_j_jmhi_2014_05_002 crossref_primary_10_1016_j_clml_2021_09_023 crossref_primary_10_3109_10428194_2011_607527 crossref_primary_10_1016_j_leukres_2014_05_023 crossref_primary_10_1111_j_1365_2559_2012_04185_x crossref_primary_10_1200_JCO_2017_72_7925 crossref_primary_10_3390_biom11101398 crossref_primary_10_1186_1756_8722_6_89 crossref_primary_10_1002_ajh_23361 crossref_primary_10_1053_j_seminoncol_2017_10_003 crossref_primary_10_1158_1078_0432_CCR_15_0468 crossref_primary_10_1007_s13193_016_0602_5 crossref_primary_10_1080_14737140_2021_1918548 crossref_primary_10_3389_fonc_2025_1632039 crossref_primary_10_1111_bjh_13198 crossref_primary_10_1177_2040620716673787 crossref_primary_10_1016_j_imlet_2014_03_001 crossref_primary_10_1038_leu_2016_238 crossref_primary_10_1016_j_patol_2011_11_006 crossref_primary_10_1080_17474086_2021_1962278 crossref_primary_10_1016_j_clml_2019_07_001 crossref_primary_10_1002_prca_201400145 crossref_primary_10_1016_j_semcancer_2016_05_001 crossref_primary_10_3109_10428194_2012_698274 crossref_primary_10_1053_j_seminhematol_2016_05_007 crossref_primary_10_1016_j_imbio_2019_11_007 crossref_primary_10_1186_s40880_019_0365_9 crossref_primary_10_3109_10428194_2014_951849 crossref_primary_10_1016_j_mpdhp_2015_09_002 crossref_primary_10_1016_j_leukres_2020_106427 crossref_primary_10_1016_j_lrr_2025_100519 crossref_primary_10_1016_j_ajpath_2016_07_002 crossref_primary_10_1016_j_critrevonc_2016_10_006 crossref_primary_10_2298_MPNS2304092R crossref_primary_10_1038_modpathol_2016_92 crossref_primary_10_3322_caac_21438 crossref_primary_10_3390_pathogens9010068 crossref_primary_10_4274_meandros_galenos_2023_74317 crossref_primary_10_3892_mmr_2017_7158 crossref_primary_10_3390_bioengineering10020197 crossref_primary_10_3390_cancers14061469 crossref_primary_10_1186_1471_2407_14_335 crossref_primary_10_1136_jclinpath_2012_201425 crossref_primary_10_1182_blood_2017_09_772632 crossref_primary_10_4161_onci_27089 crossref_primary_10_1186_1756_8722_6_62 crossref_primary_10_1053_j_seminhematol_2016_05_011 crossref_primary_10_1016_j_cyto_2014_12_012 crossref_primary_10_1182_blood_2015_10_671826 crossref_primary_10_1038_ng_2900 crossref_primary_10_3389_fimmu_2018_01358 crossref_primary_10_1038_mt_2013_14 crossref_primary_10_1186_s12885_020_07374_3 crossref_primary_10_1080_10428194_2018_1488254 crossref_primary_10_1124_jpet_117_244947 crossref_primary_10_3389_fphar_2025_1553331 crossref_primary_10_1053_j_seminhematol_2013_02_002 crossref_primary_10_1007_s00259_013_2658_6 crossref_primary_10_1016_j_clml_2023_06_006 crossref_primary_10_1016_S2152_2650_21_01258_1 crossref_primary_10_1177_20406207221149245 crossref_primary_10_1007_s12308_014_0214_3 crossref_primary_10_1007_s13277_016_5198_4 crossref_primary_10_1016_S0140_6736_12_60035_X crossref_primary_10_1002_ccr3_246 crossref_primary_10_1158_1078_0432_CCR_12_3064 crossref_primary_10_3390_ijms22073302 crossref_primary_10_1111_bjh_12759 crossref_primary_10_1016_j_humpath_2011_09_002 crossref_primary_10_1111_bjh_12878 crossref_primary_10_3389_fimmu_2023_1155468 crossref_primary_10_1016_j_bbmt_2017_04_013 crossref_primary_10_1182_bloodadvances_2018017244 crossref_primary_10_3892_mco_2015_646 crossref_primary_10_1097_MPH_0000000000002346 crossref_primary_10_1002_ijc_28189 crossref_primary_10_3390_cancers14051360 crossref_primary_10_1007_s00441_014_2052_0 crossref_primary_10_1111_his_12458 crossref_primary_10_1016_j_ctrv_2019_06_002 crossref_primary_10_1111_bjh_15695 crossref_primary_10_4137_CMO_S6637 crossref_primary_10_1016_j_blre_2022_100986 crossref_primary_10_1371_journal_pone_0124614 crossref_primary_10_3892_or_2013_2244 crossref_primary_10_1007_s00277_014_2044_x crossref_primary_10_1182_blood_2011_07_362475 crossref_primary_10_1182_blood_2013_02_484451 crossref_primary_10_1016_j_thromres_2014_01_020 crossref_primary_10_1200_JCO_2011_41_0910 crossref_primary_10_3390_cancers16234070 crossref_primary_10_1177_2040620718761777 crossref_primary_10_1038_leu_2016_232 crossref_primary_10_1182_blood_2011_09_378398 crossref_primary_10_1016_j_hoc_2013_10_004 crossref_primary_10_3389_fonc_2024_1397053 crossref_primary_10_3390_cancers15215217 crossref_primary_10_1073_pnas_1517389112 crossref_primary_10_1158_1078_0432_CCR_14_1845 crossref_primary_10_3390_cancers14133222 crossref_primary_10_1016_j_critrevonc_2013_11_002 crossref_primary_10_3389_fonc_2022_1000762 crossref_primary_10_1182_bloodadvances_2020003664 crossref_primary_10_1016_j_clml_2019_11_021 crossref_primary_10_1080_17474086_2016_1242404 crossref_primary_10_1111_1759_7714_15197 crossref_primary_10_1371_journal_pone_0248259 crossref_primary_10_1016_j_critrevonc_2013_09_004 crossref_primary_10_1002_ijc_27314 crossref_primary_10_1111_bjh_15676 crossref_primary_10_1038_nrc3774 crossref_primary_10_1309_AJCP61TLMXLSLJYS crossref_primary_10_1080_14712598_2020_1830056 crossref_primary_10_1016_j_ejrad_2021_109793 crossref_primary_10_1182_blood_2013_04_497586 crossref_primary_10_1097_PAP_0000000000000002 crossref_primary_10_1093_labmed_lmx065 crossref_primary_10_1016_j_clml_2015_02_002 crossref_primary_10_1007_s00761_013_2633_7 crossref_primary_10_1080_10428194_2016_1239263 crossref_primary_10_1016_j_ejca_2013_05_024 crossref_primary_10_1016_j_semcancer_2015_02_002 crossref_primary_10_1182_blood_2019000847 crossref_primary_10_1016_j_semcancer_2015_02_001 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2010.32.8401 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 21483001 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Canadian Institutes of Health Research grantid: 178536 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c396t-a70171eaede004e49f3e983da3d469c794e2e1c68487c89c937c858f3e79d4fe2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 297 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000290382300015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Thu Oct 02 05:30:59 EDT 2025 Thu Apr 03 06:59:13 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c396t-a70171eaede004e49f3e983da3d469c794e2e1c68487c89c937c858f3e79d4fe2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 21483001 |
| PQID | 865694858 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_865694858 pubmed_primary_21483001 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-May-10 20110510 |
| PublicationDateYYYYMMDD | 2011-05-10 |
| PublicationDate_xml | – month: 05 year: 2011 text: 2011-May-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2011 |
| SSID | ssj0014835 |
| Score | 2.5091574 |
| SecondaryResourceType | review_article |
| Snippet | Hodgkin's lymphoma (HL) represents the most common subtype of malignant lymphoma in young people in the Western world. Most patients can be cured with modern... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1812 |
| SubjectTerms | Biomarkers, Tumor Cell Communication Chemokines - physiology Cytokines - physiology Dendritic Cells, Follicular - immunology Herpesvirus 4, Human - isolation & purification Hodgkin Disease - etiology Hodgkin Disease - therapy Humans Macrophages - physiology Signal Transduction T-Lymphocyte Subsets - immunology |
| Title | Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21483001 https://www.proquest.com/docview/865694858 |
| Volume | 29 |
| WOSCitedRecordID | wos000290382300015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8JAEJ74ivHiA1_4yh4MXqik3cJuvRhDJMQI9oAJN1L2QRqkRYsm_Htn20W4GA9eemh3k2Z2dvabx84HcE0Z-j0anZyhzKNVwnMiPBccV1Cm8YuwK_3Mul3e7wehrc3JbFnlwibmhlqmwsTIaxyBh-lkwu-n744hjTLJVcugsQ6bFJGMqehi_WUSwec5v6YhbkUQWa_bLCXqRe2p-VKUdVHvFl0c93d8mZ8zrb1__uE-7FqASR4KjTiANZWUYLtjU-glqIRFs-p5lfSWd6-yKqmQcNnGen4I486COZcY2uJ0ZKxinJFUk3YqR-M4ucnI2xy1IZ1EdyRODP40kQeiLFOpGYr4ksSTHOSvvJmYMsCVO3ZH8Np67DXbjqVmcAQNGjMnYqbPjoqUVLjLlB9oqgJOZUQl-tsCN7nylCsaHP0hwQOBIEigZHAUC6SvlXcMG0maqFMgQiKG0NpDrBP4nkIAxZmOho1hXTCpXVUGshD3AFXf5DOiRKWf2eBH4GU4KZZsMC1adAw8s_ioAmd_Tz6HnSJObDqyXsCmxm2vLmFLfM3i7OMqVyl8dsPON7PO17s |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+pathogenesis+of+Hodgkin%27s+lymphoma%3A+increasing+evidence+of+the+importance+of+the+microenvironment&rft.jtitle=Journal+of+clinical+oncology&rft.au=Steidl%2C+Christian&rft.au=Connors%2C+Joseph+M&rft.au=Gascoyne%2C+Randy+D&rft.date=2011-05-10&rft.eissn=1527-7755&rft.volume=29&rft.issue=14&rft.spage=1812&rft_id=info:doi/10.1200%2FJCO.2010.32.8401&rft_id=info%3Apmid%2F21483001&rft_id=info%3Apmid%2F21483001&rft.externalDocID=21483001 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |